MON-P054: Diarrhea is a Risk Factor for Liver Injury and May Lead to Intestinal Failure Associated Liver Disease in Critical Illness

2016 ◽  
Vol 35 ◽  
pp. S173
Author(s):  
N. Lefel ◽  
F. Schaap ◽  
D. Bergmans ◽  
S.O. Damink ◽  
M. Van de Poll
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Critical Illness ◽  
Liver Injury ◽  
Intestinal Failure

scholarly journals Association between the concurrence of pre-existing chronic liver disease and worse prognosis in patients with an herb-Polygonum multiflorumthunb. induced liver injury: a case-control study from a specialised liver disease center in China

BMJ Open ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. e023567 ◽  
Author(s):  
Jing Jing ◽  
Rui-lin Wang ◽  
Xin-yan Zhao ◽  
Yun Zhu ◽  
Ming Niu ◽  
...  
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Liver Injury ◽  
Liver Diseases ◽  
Independent Risk Factor ◽  
Case Control Study ◽  
Case Control ◽  
Chronic Liver ◽  
Control Study ◽  
Worse Prognosis

ObjectivesThe present study aimed to evaluate the association between the concurrence of pre-existing chronic liver diseases (CLD) and worse prognosis in patients with HILI.DesignA case–control study.SettingTertiary hospital specialising in liver diseases in China.Participants145 hospitalised HILI patients were assessed with respect to prognosis by comparing HILI with or without pre-existing CLD from February 2007 to January 2017. Twenty-five HILI cases with pre-existing alcoholic liver disease (ALD) or non-alcoholic fatty liver disease (NAFLD) and 200 ALD or NAFLD controls matched 1:8 for sex, age (±4 years old), body mass index (±2 kg/m2), the type of CLD, alcohol intake (±5 g/d) and the presence or absence of cirrhosis.Primary outcome measuresMortality and chronicity in HILI patients with or without pre-existing CLD, and matched CLD patients.ResultsOf the 193 714 hospitalised patients with liver diseases, 5703 patients met the diagnostic criteria for drug-induced liver injury (DILI), which was attributed toPolygonum multiflorumThunb. (PMT) in 145 patients. Among these HILI patients, 22.8% (33 of 145) had pre-existing CLD, including 17 (51.5%) with ALD, 8 (24.2%) with NAFLD, 5 (15.2%) with chronic viral hepatitis and 3 (9.1%) with autoimmune liver disease. Compared with HILI patients without CLD, HILI patients with pre-existing CLD showed higher mortality (0.9% vs 9.1%, p=0.037) and higher chronicity (12.5% vs 30.3%, p=0.016). Compared with matched ALD (136 patients) or NAFLD (64 patients) patients, HILI patients with pre-existing ALD showed higher chronicity (35.3% vs 11.8%, p=0.019). Multivariate logistic regression analysis found that concurrence of pre-existing CLD was an independent risk factor for both of chronicity and mortality (OR 3.966, 95% CI 1.501 to 10.477, p=0.005), especially the chronicity (OR 3.035, 95% CI 1.115 to 8.259, p=0.030).ConclusionsConcurrence of pre-existing CLD could be an independent risk factor for worse prognosis, especially chronicity, in PMT-related HILI.

scholarly journals COVID-19 Related to Liver Impairment and Its Impact on Chronic Liver Disease

2020 ◽  
Vol 21 (3) ◽  
pp. 220-225
Author(s):  
Andri Sanityoso Sulaiman ◽  
Juferdy Kurniawan ◽  
Chyntia Olivia Maurine Jasirwan ◽  
Saut HH Nababan ◽  
Kemal F Calista ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Health Care ◽  
Risk Factor ◽  
Liver Disease ◽  
Liver Injury ◽  
Virus Infection ◽  
Severe Illness ◽  
Liver Impairment ◽  
Transplant Patients ◽  
Effective Drugs

By late December 2019, a novel beta-coronavirus, named as COVID-19 (2019-nCoV), was discovered in Wuhan, Hubei Province, China which epidemiologically linked to a Huanan seafood market in Wuhan. Coronavirus Disease 2019 or COVID-19 cases are growing rapidly from Wuhan to many countries, finding the health care system unprepared to face this threat. No effective drugs are clinically approved to manage the disease and strategies to protect the most vulnerable from developing severe illness and infection is still unclear. Information on how COVID-19 virus infection may affects many organs, especially the liver and the relevance of pre-existing liver disease in patients as a risk factor for the infection or disease severity are still scarce and inconclusive. Besides, the recommendation and consideration in liver transplant patients, hepatocellular carcinoma, or patient on immunosuppressive therapy still need further analysis Therefore, the information on the mechanism and treatment of COVID-19 related liver injury in patients with or without pre-existing liver disease should be considered.

Mechanisms of liver damage in COVID-19

2020 ◽  
Vol 1 (19) ◽  
pp. 39-46
Author(s):  
T. V. Pinchuk ◽  
N. V. Orlova ◽  
T. G. Suranova ◽  
T. I. Bonkalo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Risk Factor ◽  
Liver Disease ◽  
Liver Function ◽  
Liver Damage ◽  
The World ◽  
Coronavirus Infection ◽  
The Impact ◽  
Analyze Data

At the end of 2019, a new coronavirus (SARS-CoV-2) was discovered in China, causing the coronavirus infection COVID-19. The ongoing COVID-19 pandemic poses a major challenge to health systems around the world. There is still little information on how infection affects liver function and the significance of pre-existing liver disease as a risk factor for infection and severe COVID-19. In addition, some drugs used to treat the new coronavirus infection are hepatotoxic. In this article, we analyze data on the impact of COVID-19 on liver function, as well as on the course and outcome of COVID-19 in patients with liver disease, including hepatocellular carcinoma, or those on immunosuppressive therapy after liver transplantation.

Sign in / Sign up

Export Citation Format

Share Document